{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T13:40:47Z","timestamp":1770903647449,"version":"3.50.1"},"publisher-location":"Cham","reference-count":227,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783319571911","type":"print"},{"value":"9783319571935","type":"electronic"}],"license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017]]},"DOI":"10.1007\/978-3-319-57193-5_4","type":"book-chapter","created":{"date-parts":[[2017,7,3]],"date-time":"2017-07-03T09:03:24Z","timestamp":1499072604000},"page":"93-128","source":"Crossref","is-referenced-by-count":13,"title":["Huntington\u2019s Disease: Pathogenic Mechanisms and Therapeutic Targets"],"prefix":"10.1007","author":[{"given":"Dean J.","family":"Wright","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thibault","family":"Renoir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura J.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony J.","family":"Hannan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,7,4]]},"reference":[{"key":"4_CR1","doi-asserted-by":"crossref","unstructured":"Paulsen JS, Langbehn DR, Stout JC, Aylward E, Ross CA, Nance M, Guttman M, Johnson S, MacDonald M, Beglinger LJ, Duff K, Kayson E, Biglan K, Shoulson I, Oakes D, Hayden M, Predict-HD Investigators and Coordinators of the Huntington Study Group (2008) Detection of Huntington\u2019s disease decades before diagnosis: the predict-HD study. J Neurol Neurosurg Psychiatry 79:874\u2013880","DOI":"10.1136\/jnnp.2007.128728"},{"key":"4_CR2","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1037\/a0018905","volume":"24","author":"KC Rowe","year":"2010","unstructured":"Rowe KC, Paulsen JS, Langbehn DR, Duff K, Beglinger LJ, Wang C, O\u2019Rourke JJF, Stout JC, Moser DJ, Huntingto P-HI (2010) Self-paced timing detects and tracks change in prodromal Huntington disease. Neuropsychology 24:435\u2013442","journal-title":"Neuropsychology"},{"key":"4_CR3","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.gaitpost.2009.07.006","volume":"30","author":"AK Rao","year":"2009","unstructured":"Rao AK, Louis ED, Marder KS (2009) Clinical assessment of mobility and balance impairments in pre-symptomatic Huntington\u2019s disease. Gait Posture 30:391\u2013393","journal-title":"Gait Posture"},{"key":"4_CR4","first-page":"320","volume":"26","author":"G Huntington","year":"1872","unstructured":"Huntington G (1872) On Chorea Med Surg Rep 26:320\u2013321","journal-title":"On Chorea Med Surg Rep"},{"key":"4_CR5","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1177\/089198879801100204","volume":"11","author":"MA Nance","year":"1998","unstructured":"Nance MA (1998) Huntington disease: clinical, genetic, and social aspects. J Geriatr Psychiatry Neurol 11:61\u201370","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"4_CR6","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/s11910-011-0215-x","volume":"11","author":"JS Paulsen","year":"2011","unstructured":"Paulsen JS (2011) Cognitive impairment in Huntington disease: diagnosis and treatment. Curr Neurol Neurosci Rep 11:474\u2013483","journal-title":"Curr Neurol Neurosci Rep"},{"key":"4_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1037\/a0020937","volume":"25","author":"JC Stout","year":"2011","unstructured":"Stout JC, Paulsen JS, Queller S, Solomon AC, Whitlock KB, Campbell JC, Carlozzi N, Duff K, Beglinger LJ, Langbehn DR, Johnson SA, Biglan KM, Aylward EH, Coordinat P-HI (2011) Neurocognitive signs in prodromal Huntington disease. Neuropsychology 25:1\u201314","journal-title":"Neuropsychology"},{"key":"4_CR8","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1016\/j.neuropsychologia.2010.05.019","volume":"48","author":"AJ Calder","year":"2010","unstructured":"Calder AJ, Keane J, Young AW, Lawrence AD, Mason S, Barker RA (2010) The relation between anger and different forms of disgust: implications for emotion recognition impairments in Huntington\u2019s disease. Neuropsychologia 48:2719\u20132729","journal-title":"Neuropsychologia"},{"key":"4_CR9","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/j.neuropsychologia.2006.01.015","volume":"44","author":"A Montoya","year":"2006","unstructured":"Montoya A, Pelletier M, Menear M, Duplessis E, Richer F, Lepage M (2006) Episodic memory impairment in Huntington\u2019s disease: a meta-analysis. Neuropsychologia 44:1984\u20131994","journal-title":"Neuropsychologia"},{"key":"4_CR10","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1177\/0891988710383573","volume":"23","author":"A Sturrock","year":"2010","unstructured":"Sturrock A, Leavitt BR (2010) The clinical and genetic features of Huntington disease. J Geriatr Psychiatry Neurol 23:243\u2013259","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"4_CR11","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.parkreldis.2016.02.008","volume":"25","author":"S Martinez-Horta","year":"2016","unstructured":"Martinez-Horta S, Perez-Perez J, van Duijn E, Fernandez-Bobadilla R, Carceller M, Pagonabarraga J, Pascual-Sedano B, Campolongo A, Ruiz-Idiago J, Sampedro F, Landwehrmeyer GB, Kulisevsky J (2016) Neuropsychiatric symptoms are very common in premanifest and early stage Huntington\u2019s disease. Parkinsonism Relat Disord 25:58\u201364","journal-title":"Parkinsonism Relat Disord"},{"key":"4_CR12","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0165-1781(01)00257-8","volume":"102","author":"GE Berrios","year":"2001","unstructured":"Berrios GE, Wagle AC, Markova IS, Wagle SA, Ho LW, Rubinsztein DC, Whittaker J, Ffrench-Constant C, Kershaw A, Rosser A, Bak T, Hodges JR (2001) Psychiatric symptoms and CAG repeats in neurologically asymptomatic Huntington\u2019s disease gene carriers. Psychiatry Res 102:217\u2013225","journal-title":"Psychiatry Res"},{"key":"4_CR13","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.biopsych.2006.11.034","volume":"62","author":"K Duff","year":"2007","unstructured":"Duff K, Paulsen JS, Beglinger LJ, Langbehn DR, Stout JC, Predict HDI (2007) Psychiatric symptoms in Huntington\u2019s disease before diagnosis: the predict-HD study. Biol Psychiatry 62:1341\u20131346","journal-title":"Biol Psychiatry"},{"key":"4_CR14","first-page":"192","volume":"15","author":"SC Kirkwood","year":"2002","unstructured":"Kirkwood SC, Siemers E, Viken R, Hodes ME, Conneally PM, Christian JC, Foroud T (2002) Longitudinal personality changes among presymptomatic Huntington disease gene carriers. Neuropsychiatry Neuropsychol Behav Neurol 15:192\u2013197","journal-title":"Neuropsychiatry Neuropsychol Behav Neurol"},{"key":"4_CR15","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0022-3956(02)00054-7","volume":"36","author":"SC Kirkwood","year":"2002","unstructured":"Kirkwood SC, Siemers E, Viken RJ, Hodes ME, Conneally PM, Christian JC, Foroud T (2002) Evaluation of psychological symptoms among presymptomatic HD gene carriers as measured by selected MMPI scales. J Psychiatr Res 36:377\u2013382","journal-title":"J Psychiatr Res"},{"key":"4_CR16","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1017\/S109285290002201X","volume":"6","author":"JR Slaughter","year":"2001","unstructured":"Slaughter JR, Martens MP, Slaughter KA (2001) Depression and Huntington\u2019s disease: prevalence, clinical manifestations, etiology, and treatment. CNS Spectr 6:306\u2013326","journal-title":"CNS Spectr"},{"key":"4_CR17","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1136\/jnnp.2006.103309","volume":"78","author":"CL Julien","year":"2007","unstructured":"Julien CL, Thompson JC, Wild S, Yardumian P, Snowden JS, Turner G, Craufurd D (2007) Psychiatric disorders in preclinical Huntington\u2019s disease. J Neurol Neurosurg Psychiatry 78:939\u2013943","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"4_CR18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jpsychores.2015.11.003","volume":"80","author":"M Dale","year":"2016","unstructured":"Dale M, Maltby J, Shimozaki S, Cramp R, Rickards H (2016) Disease stage, but not sex, predicts depression and psychological distress in Huntington\u2019s disease: a European population study. J Psychosom Res 80:17\u201322","journal-title":"J Psychosom Res"},{"key":"4_CR19","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1089\/gte.2004.8.114","volume":"8","author":"A Codori","year":"2004","unstructured":"Codori A, Slavney PR, Rosenblatt A, Brandt J (2004) Prevalence of major depression one year after predictive testing for Huntington\u2019s disease. Genet Test 8:114\u2013119","journal-title":"Genet Test"},{"key":"4_CR20","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/hmg\/ddn385","volume":"18","author":"TY Pang","year":"2009","unstructured":"Pang TY, Du X, Zajac MS, Howard ML, Hannan AJ (2009) Altered serotonin receptor expression is associated with depression-related behavior in the R6\/1 transgenic mouse model of Huntington\u2019s disease. Hum Mol Genet 18:753\u2013766","journal-title":"Hum Mol Genet"},{"key":"4_CR21","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/brain\/awp006","volume":"132","author":"MA Pouladi","year":"2009","unstructured":"Pouladi MA, Graham RK, Karasinska JM, Xie Y, Santos RD, Petersen A, Hayden MR (2009) Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin. Brain 132:919\u2013932","journal-title":"Brain"},{"key":"4_CR22","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejphar.2015.10.033","volume":"769","author":"S Jamwal","year":"2015","unstructured":"Jamwal S, Kumar P (2015) Antidepressants for neuroprotection in Huntington\u2019s disease: a review. Eur J Pharmacol 769:33\u201342","journal-title":"Eur J Pharmacol"},{"key":"4_CR23","doi-asserted-by":"crossref","unstructured":"Mielcarek, M., 2015. Huntington\u2019s disease is a multi-system disorder. Rare Dis 3, e1058464.","DOI":"10.1080\/21675511.2015.1058464"},{"key":"4_CR24","first-page":"231","volume":"5","author":"R Wang","year":"2014","unstructured":"Wang R, Ross CA, Cai H, Cong WN, Daimon CM, Carlson OD, Egan JM, Siddiqui S, Maudsley S, Martin B (2014) Metabolic and hormonal signatures in pre-manifest and manifest Huntington\u2019s disease patients. Front Physiol 5:231","journal-title":"Front Physiol"},{"key":"4_CR25","doi-asserted-by":"crossref","unstructured":"MacDonald ME, Ambrose CM, Duyao MP, Myers RH, Lin C, Srinidhi L, Barnes G, Taylor SA, James M, Groot N, MacFarlane H, Jenkins B, Anderson MA, Wexler NS, Gusella JF, Bates GP, Baxendale S, Hummerich H, Kirby S, North M, Youngman S, Mott R, Zehetner G, Sedlacek Z, Poustka A, Frischauf A-M, Lehrach H, Buckler AJ, Church D, Doucette-Stamm L, O'Donovan MC, Riba-Ramirez L, Shah M, Stanton VP, Strobel SA, Draths KM, Wales JL, Dervan P, Housman DE, Altherr M, Shiang R, Thompson L, Fielder T, Wasmuth JJ, Tagle D, Valdes J, Elmer L, Allard M, Castilla L, Swaroop M, Blanchard K, Collins FS, Snell R, Holloway T, Gillespie K, Datson N, Shaw D, Harper PS (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. Cell 72:971\u2013983","DOI":"10.1016\/0092-8674(93)90585-E"},{"key":"4_CR26","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/0896-6273(93)90127-D","volume":"11","author":"SH Li","year":"1993","unstructured":"Li SH, Schilling G, Young WS 3rd, Li XJ, Margolis RL, Stine OC, Wagster MV, Abbott MH, Franz ML, Ranen NG (1993) Huntington\u2019s disease gene (IT15) is widely expressed in human and rat tissues. Neuron 11:985\u2013993","journal-title":"Neuron"},{"key":"4_CR27","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/ng1193-259","volume":"5","author":"TV Strong","year":"1993","unstructured":"Strong TV, Tagle DA, Valdes JM, Elmer LW, Boehm K, Swaroop M, Kaatz KW, Collins FS, Albin RL (1993) Widespread expression of the human and rat Huntington\u2019s disease gene in brain and nonneural tissues. Nat Genet 5:259\u2013265","journal-title":"Nat Genet"},{"key":"4_CR28","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/ng0595-104","volume":"10","author":"Y Trottier","year":"1995","unstructured":"Trottier Y, Devys D, Imbert G, Saudou F, An I, Lutz Y, Weber C, Agid Y, Hirsch EC, Mandel JL (1995) Cellular localization of the Huntington\u2019s disease protein and discrimination of the normal and mutated form. Nat Genet 10:104\u2013110","journal-title":"Nat Genet"},{"key":"4_CR29","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1089\/ars.2006.8.2061","volume":"8","author":"SE Browne","year":"2006","unstructured":"Browne SE, Beal MF (2006) Oxidative damage in Huntington\u2019s disease pathogenesis. Antioxid Redox Signal 8:2061\u20132073","journal-title":"Antioxid Redox Signal"},{"key":"4_CR30","doi-asserted-by":"crossref","unstructured":"Voisine, C., Varma, H., Walker, N., Bates, E.A., Stockwell, B.R., Hart, A.C., 2007. Identification of potential therapeutic drugs for Huntington\u2019s disease using Caenorhabditis elegans. PLoS One 2, e504.","DOI":"10.1371\/journal.pone.0000504"},{"key":"4_CR31","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4161\/fly.19999","volume":"6","author":"EW Green","year":"2012","unstructured":"Green EW, Campesan S, Breda C, Sathyasaikumar KV, Muchowski PJ, Schwarcz R, Kyriacou CP, Giorgini F (2012) Drosophila eye color mutants as therapeutic tools for Huntington disease. Fly 6:117\u2013120","journal-title":"Fly"},{"key":"4_CR32","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","volume":"87","author":"L Mangiarini","year":"1996","unstructured":"Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies SW, Bates GP (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87:493\u2013506","journal-title":"Cell"},{"key":"4_CR33","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/hmg\/ddg075","volume":"12","author":"S Horsten von","year":"2003","unstructured":"von Horsten S, Schmitt I, Nguyen HP, Holzmann C, Schmidt T, Walther T, Bader M, Pabst R, Kobbe P, Krotova J, Stiller D, Kask A, Vaarmann A, Rathke-Hartlieb S, Schulz JB, Grasshoff U, Bauer I, Vieira-Saecker AMM, Paul M, Jones L, Lindenberg KS, Landwehrmeyer B, Bauer A, Li XJ, Riess O (2003) Transgenic rat model of Huntington\u2019s disease. Hum Mol Genet 12:617\u2013624","journal-title":"Hum Mol Genet"},{"key":"4_CR34","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/nature06975","volume":"453","author":"SH Yang","year":"2008","unstructured":"Yang SH, Cheng PH, Banta H, Piotrowska-Nitsche K, Yang JJ, Cheng ECH, Snyder B, Larkin K, Liu J, Fang ZH, Smith Y, Bachevalier J, Zola SM, Li SH, Li XJ, Chan AWS (2008) Towards a transgenic model of Huntington\u2019s disease in a non-human primate. Nature 453:921\u2013924","journal-title":"Nature"},{"key":"4_CR35","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/hmg\/8.3.397","volume":"8","author":"G Schilling","year":"1999","unstructured":"Schilling G, Becher MW, Sharp AH, Jinnah HA, Duan K, Kotzuk JA, Slunt HH, Ratovitski T, Cooper JK, Jenkins NA, Copeland NG, Price DL, Ross CA, Borchelt DR (1999) Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum Mol Genet 8:397\u2013407","journal-title":"Hum Mol Genet"},{"key":"4_CR36","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0896-6273(00)80764-3","volume":"23","author":"JG Hodgson","year":"1999","unstructured":"Hodgson JG, Agopyan N, Gutekunst C-A, Leavitt BR, LePiane F, Singaraja R, Smith DJ, Bissada N, McCutcheon K, Nasir J, Jamot L, Li X-J, Stevens ME, Rosemond E, Roder JC, Phillips AG, Rubin EM, Hersch SM, Hayden MR (1999) A YAC mouse model for Huntington\u2019s disease with full-length mutant Huntingtin, cytoplasmic toxicity, and selective striatal Neurodegeneration. Neuron 23:181\u2013192","journal-title":"Neuron"},{"key":"4_CR37","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.bbadis.2009.04.001","volume":"1792","author":"RJ Ferrante","year":"2009","unstructured":"Ferrante RJ (2009) Mouse models of Huntington\u2019s disease and methodological considerations for therapeutic trials. Biochim Biophys Acta 1792:506\u2013520","journal-title":"Biochim Biophys Acta"},{"issue":"7","key":"4_CR38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0022133","volume":"6","author":"T Renoir","year":"2011","unstructured":"Renoir T, Zajac MS, Du X, Pang T, Leang L, Chevarin C, Lanfumey L, Hannan AJ (2011) Sexually dimorphic serotonergic dysfunction in a mouse model of Huntington\u2019s disease and depression. PLoS One 6(7):e22133","journal-title":"PLoS One"},{"key":"4_CR39","doi-asserted-by":"crossref","first-page":"10428","DOI":"10.1523\/JNEUROSCI.19-23-10428.1999","volume":"19","author":"LA Lione","year":"1999","unstructured":"Lione LA, Carter RJ, Hunt MJ, Bates GP, Morton AJ, Dunnett SB (1999) Selective discrimination learning impairments in mice expressing the human Huntington\u2019s disease mutation. J Neurosci 19:10428\u201310437","journal-title":"J Neurosci"},{"key":"4_CR40","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10863-010-9290-y","volume":"42","author":"C Turner","year":"2010","unstructured":"Turner C, Schapira AH (2010) Mitochondrial matters of the brain: the role in Huntington\u2019s disease. J Bioenerg Biomembr 42:193\u2013198","journal-title":"J Bioenerg Biomembr"},{"key":"4_CR41","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/35008142","volume":"404","author":"A Dellen van","year":"2000","unstructured":"van Dellen A, Blakemore C, Deacon R, York D, Hannan AJ (2000) Delaying the onset of Huntington\u2019s in mice. Nature 404:721\u2013722","journal-title":"Nature"},{"key":"4_CR42","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1602\/neurorx.1.3.298","volume":"1","author":"SM Hersch","year":"2004","unstructured":"Hersch SM, Ferrante RJ (2004) Translating therapies for Huntington\u2019s disease from genetic animal models to clinical trials. NeuroRx 1:298\u2013306","journal-title":"NeuroRx"},{"key":"4_CR43","doi-asserted-by":"crossref","first-page":"6182","DOI":"10.1523\/JNEUROSCI.0857-08.2008","volume":"28","author":"M Gray","year":"2008","unstructured":"Gray M, Shirasaki DI, Cepeda C, Andr\u00e9 VM, Wilburn B, Lu X-H, Tao J, Yamazaki I, Li S-H, Sun YE, Li X-J, Levine MS, Yang XW (2008) Full-length human mutant Huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J Neurosci 28:6182\u20136195","journal-title":"J Neurosci"},{"key":"4_CR44","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/nrn3570","volume":"14","author":"MA Pouladi","year":"2013","unstructured":"Pouladi MA, Morton AJ, Hayden MR (2013) Choosing an animal model for the study of Huntington\u2019s disease. Nat Rev Neurosci 14:708\u2013721","journal-title":"Nat Rev Neurosci"},{"key":"4_CR45","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3389\/fncel.2013.00037","volume":"7","author":"JC Niclis","year":"2013","unstructured":"Niclis JC, Pinar A, Haynes JM, Alsanie W, Jenny R, Dottori M, Cram DS (2013) Characterization of forebrain neurons derived from late-onset Huntington\u2019s disease human embryonic stem cell lines. Front Cell Neurosci 7:37","journal-title":"Front Cell Neurosci"},{"key":"4_CR46","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.cell.2008.07.041","volume":"134","author":"IH Park","year":"2008","unstructured":"Park IH, Arora N, Huo H, Maherali N, Ahfeldt T, Shimamura A, Lensch MW, Cowan C, Hochedlinger K, Daley GQ (2008) Disease-specific induced pluripotent stem cells. Cell 134:877\u2013886","journal-title":"Cell"},{"key":"4_CR47","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0166-2236(00)01721-5","volume":"24","author":"E Cattaneo","year":"2001","unstructured":"Cattaneo E, Rigamonti D, Goffredo D, Zuccato C, Squitieri F, Sipione S (2001) Loss of normal huntingtin function: new developments in Huntington\u2019s disease research. Trends Neurosci 24:182\u2013188","journal-title":"Trends Neurosci"},{"key":"4_CR48","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/nrn1806","volume":"6","author":"E Cattaneo","year":"2005","unstructured":"Cattaneo E, Zuccato C, Tartari M (2005) Normal huntingtin function: an alternative approach to Huntington\u2019s disease. Nat Rev Neurosci 6:919\u2013930","journal-title":"Nat Rev Neurosci"},{"key":"4_CR49","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1126\/science.7618107","volume":"269","author":"M Duyao","year":"1995","unstructured":"Duyao M, Auerbach A, Ryan A, Persichetti F, Barnes G, McNeil S, Ge P, Vonsattel J, Gusella J, Joyner A, et a (1995) Inactivation of the mouse Huntington\u2019s disease gene homolog Hdh. Science 269:407\u2013410","journal-title":"Science"},{"key":"4_CR50","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/0092-8674(95)90542-1","volume":"81","author":"J Nasir","year":"1995","unstructured":"Nasir J, Floresco SB, O'Kusky JR, Diewert VM, Richman JM, Zeisler J, Borowski A, Marth JD, Phillips AG, Hayden MR (1995) Targeted disruption of the Huntington\u2019s disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 81:811\u2013823","journal-title":"Cell"},{"key":"4_CR51","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/ng1095-155","volume":"11","author":"S Zeitlin","year":"1995","unstructured":"Zeitlin S, Liu JP, Chapman DL, Papaioannou VE, Efstratiadis A (1995) Increased apoptosis and early embryonic lethality in mice nullizygous for the huntingtons-disease gene homolog. Nat Genet 11:155\u2013163","journal-title":"Nat Genet"},{"key":"4_CR52","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1086\/318207","volume":"68","author":"BR Leavitt","year":"2001","unstructured":"Leavitt BR, Guttman JA, Hodgson JG, Kimel GH, Singaraja R, Vogl AW, Hayden MR (2001) Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in vivo. Am J Hum Genet 68:313\u2013324","journal-title":"Am J Hum Genet"},{"key":"4_CR53","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/hmg\/ddi147","volume":"14","author":"JM Raamsdonk Van","year":"2005","unstructured":"Van Raamsdonk JM, Pearson J, Rogers DA, Bissada N, Vogl AW, Hayden MR, Leavitt BR (2005) Loss of wild-type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington disease. Hum Mol Genet 14:1379\u20131392","journal-title":"Hum Mol Genet"},{"key":"4_CR54","first-page":"615","volume":"45","author":"RH Myers","year":"1989","unstructured":"Myers RH, Leavitt J, Farrer LA, Jagadeesh J, McFarlane H, Mastromauro CA, Mark RJ, Gusella JF (1989) Homozygote for huntington disease. Am J Hum Genet 45:615\u2013618","journal-title":"Am J Hum Genet"},{"key":"4_CR55","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/326194a0","volume":"326","author":"NS Wexler","year":"1987","unstructured":"Wexler NS, Young AB, Tanzi RE, Travers H, Starostarubinstein S, Penney JB, Snodgrass SR, Shoulson I, Gomez F, Arroyo MAR, Penchaszadeh GK, Moreno H, Gibbons K, Faryniarz A, Hobbs W, Anderson MA, Bonilla E, Conneally PM, Gusella JF (1987) Homozygotes for huntingtons-disease. Nature 326:194\u2013197","journal-title":"Nature"},{"key":"4_CR56","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1523\/JNEUROSCI.20-10-03705.2000","volume":"20","author":"D Rigamonti","year":"2000","unstructured":"Rigamonti D, Bauer JH, De-Fraja C, Conti L, Sipione S, Sciorati C, Clementi E, Hackam A, Hayden MR, Li Y, Cooper JK, Ross CA, Govoni S, Vincenz C, Cattaneo E (2000) Wild-type Huntingtin protects from apoptosis upstream of caspase-3. J Neurosci 20:3705\u20133713","journal-title":"J Neurosci"},{"key":"4_CR57","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/81593","volume":"26","author":"I Dragatsis","year":"2000","unstructured":"Dragatsis I, Levine MS, Zeitlin S (2000) Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat Genet 26:300\u2013306","journal-title":"Nat Genet"},{"key":"4_CR58","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/ncb735","volume":"4","author":"FG Gervais","year":"2002","unstructured":"Gervais FG, Singaraja R, Xanthoudakis S, Gutekunst CA, Leavitt BR, Metzler M, Hackam AS, Tam J, Vaillancourt JP, Houtzager V, Rasper DM, Roy S, Hayden MR, Nicholson DW (2002) Recruitment and activation of caspase-8 by the Huntingtin-interacting protein hip-1 and a novel partners Hippi. Nat Cell Biol 4:95\u2013105","journal-title":"Nat Cell Biol"},{"key":"4_CR59","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0968-0004(03)00168-3","volume":"28","author":"P Harjes","year":"2003","unstructured":"Harjes P, Wanker EE (2003) The hunt for huntingtin function: interaction partners tell many different stories. Trends Biochem Sci 28:425\u2013433","journal-title":"Trends Biochem Sci"},{"key":"4_CR60","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1126\/science.1072613","volume":"296","author":"AW Dunah","year":"2002","unstructured":"Dunah AW, Jeong H, Griffin A, Kim YM, Standaert DG, Hersch SM, Mouradian MM, Young AB, Tanese N, Krainc D (2002) Sp1 and TAFII130 transcriptional activity disrupted in early Huntington\u2019s disease. Science 296:2238\u20132243","journal-title":"Science"},{"key":"4_CR61","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1073\/pnas.98.4.1811","volume":"98","author":"S Holbert","year":"2001","unstructured":"Holbert S, Denghien I, Kiechle T, Rosenblatt A, Wellington C, Hayden MR, Margolis RL, Ross CA, Dausset J, Ferrante RJ, N\u00e9ri C (2001) The Gln-Ala repeat transcriptional activator CA150 interacts with huntingtin: Neuropathologic and genetic evidence for a role in Huntington\u2019s disease pathogenesis. Proc Natl Acad Sci U S A 98:1811\u20131816","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4_CR62","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1093\/hmg\/9.14.2197","volume":"9","author":"A McCampbell","year":"2000","unstructured":"McCampbell A, Taylor JP, Taye AA, Robitschek J, Li M, Walcott J, Merry D, Chai Y, Paulson H, Sobue G, Fischbeck KH (2000) CREB-binding protein sequestration by expanded polyglutamine. Hum Mol Genet 9:2197\u20132202","journal-title":"Hum Mol Genet"},{"key":"4_CR63","doi-asserted-by":"crossref","first-page":"6763","DOI":"10.1073\/pnas.100110097","volume":"97","author":"JS Steffan","year":"2000","unstructured":"Steffan JS, Kazantsev A, Spasic-Boskovic O, Greenwald M, Zhu YZ, Gohler H, Wanker EE, Bates GP, Housman DE, Thompson LM (2000) The Huntington\u2019s disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc Natl Acad Sci U S A 97:6763\u20136768","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4_CR64","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1128\/MCB.22.5.1277-1287.2002","volume":"22","author":"SH Li","year":"2002","unstructured":"Li SH, Cheng AL, Zhou H, Lam S, Rao M, Li H, Li XJ (2002) Interaction of Huntington disease protein with transcriptional activator Sp1. Mol Cell Biol 22:1277\u20131287","journal-title":"Mol Cell Biol"},{"key":"4_CR65","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1093\/hmg\/8.9.1647","volume":"8","author":"JM Boutell","year":"1999","unstructured":"Boutell JM, Thomas P, Neal JW, Weston VJ, Duce J, Harper PS, Jones AL (1999) Aberrant interactions of transcriptional repressor proteins with the Huntington\u2019s disease gene product, huntingtin. Hum Mol Genet 8:1647\u20131655","journal-title":"Hum Mol Genet"},{"key":"4_CR66","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/ng1219","volume":"35","author":"C Zuccato","year":"2003","unstructured":"Zuccato C, Tartari M, Crotti A, Goffredo D, Valenza M, Conti L, Cataudella T, Leavitt BR, Hayden MR, Timmusk T, Rigamonti D, Cattaneo E (2003) Huntingtin interacts with REST\/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat Genet 35:76\u201383","journal-title":"Nat Genet"},{"key":"4_CR67","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1523\/JNEUROSCI.17-10-03623.1997","volume":"17","author":"S Alcantara","year":"1997","unstructured":"Alcantara S, Frisen J, delRio JA, Soriano E, Barbacid M, SilosSantiago I (1997) TrkB signaling is required for postnatal survival of CNS neurons and protects hippocampal and motor neurons from axotomy-induced cell death. J Neurosci 17:3623\u20133633","journal-title":"J Neurosci"},{"key":"4_CR68","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1111\/j.1460-9568.1994.tb00559.x","volume":"6","author":"HR Widmer","year":"1994","unstructured":"Widmer HR, Hefti F (1994) Neurotrophin-4\/5 promotes survival and differentiation of rat striatal neurons developing in culture. Eur J Neurosci 6:1669\u20131679","journal-title":"Eur J Neurosci"},{"key":"4_CR69","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/sj.mp.4001637","volume":"10","author":"F Angelucci","year":"2005","unstructured":"Angelucci F, Brene S, Mathe AA (2005) BDNF in schizophrenia, depression and corresponding animal models. Mol Psychiatry 10:345\u2013352","journal-title":"Mol Psychiatry"},{"key":"4_CR70","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/39885","volume":"389","author":"CA Altar","year":"1997","unstructured":"Altar CA, Cai N, Bliven T, Juhasz M, Conner JM, Acheson AL, Lindsay RM, Wiegand SJ (1997) Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature 389:856\u2013860","journal-title":"Nature"},{"key":"4_CR71","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1046\/j.1460-9568.2003.02844.x","volume":"18","author":"FR Fusco","year":"2003","unstructured":"Fusco FR, Zuccato C, Tartari M, Martorana A, De March Z, Giampa C, Cattaneo E, Bernardi G (2003) Co-localization of brain-derived neurotrophic factor (BDNF) and wild-type huntingtin in normal and quinolinic acid-lesioned rat brain. Eur J Neurosci 18:1093\u20131102","journal-title":"Eur J Neurosci"},{"key":"4_CR72","doi-asserted-by":"crossref","unstructured":"Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, Conti L, MacDonald ME, Friedlander RM, Silani V, Hayden MR, Timmusk T, Sipione S, Cattaneo E (2001) Loss of huntingtin-mediated BDNF gene transcription in Huntington\u2019s disease. Science 293:493\u2013498","DOI":"10.1126\/science.1059581"},{"key":"4_CR73","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.tcb.2009.01.005","volume":"19","author":"JP Caviston","year":"2009","unstructured":"Caviston JP, Holzbaur ELF (2009) Huntingtin as an essential integrator of intracellular vesicular trafficking. Trends Cell Biol 19:147\u2013155","journal-title":"Trends Cell Biol"},{"key":"4_CR74","doi-asserted-by":"crossref","unstructured":"Gauthier LR, Charrin BC, Borrell-Pages M, Dompierre JP, Rangone H, Cordelieres FP, De Mey J, MacDonald ME, Lessmann V, Humbert S, Saudou F (2004) Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 118:127\u2013138","DOI":"10.1016\/j.cell.2004.06.018"},{"key":"4_CR75","doi-asserted-by":"crossref","first-page":"6298","DOI":"10.1523\/JNEUROSCI.2033-12.2013","volume":"33","author":"G Liot","year":"2013","unstructured":"Liot G, Zala D, Pla P, Mottet G, Piel M, Saudou F (2013) Mutant Huntingtin alters retrograde transport of TrkB receptors in striatal dendrites. J Neurosci 33:6298\u20136309","journal-title":"J Neurosci"},{"key":"4_CR76","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.bbadis.2011.10.016","volume":"1822","author":"PH Reddy","year":"2012","unstructured":"Reddy PH, Shirendeb UP (2012) Mutant huntingtin, abnormal mitochondrial dynamics, defective axonal transport of mitochondria, and selective synaptic degeneration in Huntington\u2019s disease. Biochim Biophys Acta 1822:101\u2013110","journal-title":"Biochim Biophys Acta"},{"key":"4_CR77","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.tins.2014.09.003","volume":"38","author":"DDO Martin","year":"2015","unstructured":"Martin DDO, Ladha S, Ehrnhoefer DE, Hayden MR (2015) Autophagy in Huntington disease and huntingtin in autophagy. Trends Neurosci 38:26\u201335","journal-title":"Trends Neurosci"},{"key":"4_CR78","doi-asserted-by":"crossref","first-page":"16889","DOI":"10.1073\/pnas.1420103111","volume":"111","author":"J Ochaba","year":"2014","unstructured":"Ochaba J, Lukacsovich T, Csikos G, Zheng S, Margulis J, Salazar L, Mao K, Lau AL, Yeung SY, Humbert S, Saudou F, Klionsky DJ, Finkbeiner S, Zeitlin SO, Marsh JL, Housman DE, Thompson LM, Steffan JS (2014) Potential function for the Huntingtin protein as a scaffold for selective autophagy. Proc Natl Acad Sci U S A 111:16889\u201316894","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4_CR79","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1093\/hmg\/ddq093","volume":"19","author":"C Rose","year":"2010","unstructured":"Rose C, Menzies FM, Renna M, Acevedo-Arozena A, Corrochano S, Sadiq O, Brown SD, Rubinsztein DC (2010) Rilmenidine attenuates toxicity of polyglutamine expansions in a mouse model of Huntington\u2019s disease. Hum Mol Genet 19:2144\u20132153","journal-title":"Hum Mol Genet"},{"key":"4_CR80","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/nchembio883","volume":"3","author":"S Sarkar","year":"2007","unstructured":"Sarkar S, Perlstein EO, Imarisio S, Pineau S, Cordenier A, Maglathlin RL, Webster JA, Lewis TA, O'Kane CJ, Schreiber SL, Rubinsztein DC (2007) Small molecules enhance autophagy and reduce toxicity in Huntington\u2019s disease models. Nat Chem Biol 3:331\u2013338","journal-title":"Nat Chem Biol"},{"key":"4_CR81","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/emboj.2008.133","volume":"27","author":"E Colin","year":"2008","unstructured":"Colin E, Zala D, Liot G, Rangone H, Borrell-Pages M, Li X-J, Saudou F, Humbert S (2008) Huntingtin phosphorylation acts as a molecular switch for anterograde\/retrograde transport in neurons. EMBO J 27:2124\u20132134","journal-title":"EMBO J"},{"key":"4_CR82","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1093\/hmg\/ddn281","volume":"17","author":"D Zala","year":"2008","unstructured":"Zala D, Colin E, Rangone H, Liot G, Humbert S, Saudou F (2008) Phosphorylation of mutant huntingtin at S421 restores anterograde and retrograde transport in neurons. Hum Mol Genet 17:3837\u20133846","journal-title":"Hum Mol Genet"},{"key":"4_CR83","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1083\/jcb.200509091","volume":"172","author":"A Pal","year":"2006","unstructured":"Pal A, Severin F, Lommer B, Shevchenko A, Zerial M (2006) Huntingtin\u2013HAP40 complex is a novel Rab5 effector that regulates early endosome motility and is up-regulated in Huntington\u2019s disease. J Cell Biol 172:605\u2013618","journal-title":"J Cell Biol"},{"key":"4_CR84","doi-asserted-by":"crossref","first-page":"10045","DOI":"10.1073\/pnas.0610628104","volume":"104","author":"JP Caviston","year":"2007","unstructured":"Caviston JP, Ross JL, Antony SM, Tokito M, Holzbaur ELF (2007) Huntingtin facilitates dynein\/dynactin-mediated vesicle transport. Proc Natl Acad Sci U S A 104:10045\u201310050","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4_CR85","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.cell.2012.12.029","volume":"152","author":"D Zala","year":"2013","unstructured":"Zala D, Hinckelmann M-V, Yu H, da Cunha MML, Liot G, Cordelieres FP, Marco S, Saudou F (2013) Vesicular glycolysis provides on-board energy for fast axonal transport. Cell 152:479\u2013491","journal-title":"Cell"},{"key":"4_CR86","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ajmg.b.30992","volume":"153B","author":"DR Langbehn","year":"2010","unstructured":"Langbehn DR, Hayden MR, Paulsen JS, PREDICT-HD Investigators of the Huntington Study Group (2010) CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches. Am J Med Genet B Neuropsychiatr Genet 153B:397\u2013408","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"4_CR87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.expneurol.2011.12.013","volume":"238","author":"M Arrasate","year":"2012","unstructured":"Arrasate M, Finkbeiner S (2012) Protein aggregates in Huntington\u2019s disease. Exp Neurol 238:1\u201311","journal-title":"Exp Neurol"},{"key":"4_CR88","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1006\/nbdi.1998.0168","volume":"4","author":"MW Becher","year":"1998","unstructured":"Becher MW, Kotzuk JA, Sharp AH, Davies SW, Bates GP, Price DL, Ross CA (1998) Intranuclear neuronal inclusions in Huntington\u2019s disease and dentatorubral and pallidoluysian atrophy: correlation between the density of inclusions and IT15 CAG triplet repeat length. Neurobiol Dis 4:387\u2013397","journal-title":"Neurobiol Dis"},{"key":"4_CR89","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S0962-8924(97)88136-6","volume":"7","author":"SW Davies","year":"1997","unstructured":"Davies SW, Scherzinger E (1997) Nuclear inclusions in Huntington\u2019s disease. Trends Cell Biol 7:422","journal-title":"Trends Cell Biol"},{"key":"4_CR90","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1126\/science.277.5334.1990","volume":"277","author":"M DiFiglia","year":"1997","unstructured":"DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP, Aronin N (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277:1990\u20131993","journal-title":"Science"},{"key":"4_CR91","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1523\/JNEUROSCI.19-07-02522.1999","volume":"19","author":"CA Gutekunst","year":"1999","unstructured":"Gutekunst CA, Li SH, Yi H, Mulroy JS, Kuemmerle S, Jones R, Rye D, Ferrante RJ, Hersch SM, Li XJ (1999) Nuclear and neuropil aggregates in Huntington\u2019s disease: relationship to neuropathology. J Neurosci 19:2522\u20132534","journal-title":"J Neurosci"},{"key":"4_CR92","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/nature02998","volume":"431","author":"M Arrasate","year":"2004","unstructured":"Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S (2004) Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431:805\u2013810","journal-title":"Nature"},{"key":"4_CR93","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0092-8674(00)80513-9","volume":"90","author":"SW Davies","year":"1997","unstructured":"Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, Ross CA, Scherzinger E, Wanker EE, Mangiarini L, Bates GP (1997) Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90:537\u2013548","journal-title":"Cell"},{"key":"4_CR94","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.nbd.2005.02.013","volume":"20","author":"A Sawa","year":"2005","unstructured":"Sawa A, Nagata E, Sutcliffe S, Dulloor P, Cascio MB, Ozeki Y, Roy S, Ross CA, Snyder SH (2005) Huntingtin is cleaved by caspases in the cytoplasm and translocated to the nucleus via perinuclear sites in Huntington\u2019s disease patient lymphoblasts. Neurobiol Dis 20:267\u2013274","journal-title":"Neurobiol Dis"},{"key":"4_CR95","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s12640-010-9227-6","volume":"20","author":"K Juenemann","year":"2011","unstructured":"Juenemann K, Weisse C, Reichmann D, Kaether C, Calkhoven CF, Schilling G (2011) Modulation of mutant huntingtin N-terminal cleavage and its effect on aggregation and cell death. Neurotox Res 20:120\u2013133","journal-title":"Neurotox Res"},{"key":"4_CR96","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1531-8249(199912)46:6<842::AID-ANA6>3.0.CO;2-O","volume":"46","author":"S Kuemmerle","year":"1999","unstructured":"Kuemmerle S, Gutekunst CA, Klein AM, Li XJ, Li SH, Beal MF, Hersch SM, Ferrante RJ (1999) Huntingtin aggregates may not predict neuronal death in Huntington\u2019s disease. Ann Neurol 46:842\u2013849","journal-title":"Ann Neurol"},{"key":"4_CR97","doi-asserted-by":"crossref","first-page":"3840","DOI":"10.1073\/pnas.0409777102","volume":"102","author":"M Arrasate","year":"2005","unstructured":"Arrasate M, Finkbeiner S (2005) Automated microscope system for determining factors that predict neuronal fate. Proc Natl Acad Sci U S A 102:3840\u20133845","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4_CR98","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/00005072-198511000-00003","volume":"44","author":"JP Vonsattel","year":"1985","unstructured":"Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr (1985) Neuropathological classification of Huntington\u2019s disease. J Neuropathol Exp Neurol 44:559\u2013577","journal-title":"J Neuropathol Exp Neurol"},{"key":"4_CR99","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1523\/JNEUROSCI.11-12-03877.1991","volume":"11","author":"RJ Ferrante","year":"1991","unstructured":"Ferrante RJ, Kowall NW, Richardson EP Jr (1991) Proliferative and degenerative changes in striatal spiny neurons in Huntington\u2019s disease: a combined study using the section-Golgi method and calbindin D28k immunocytochemistry. J Neurosci 11:3877\u20133887","journal-title":"J Neurosci"},{"key":"4_CR100","volume-title":"Neuroscience","author":"D Purves","year":"2012","unstructured":"Purves D (2012) Neuroscience. Sinauer Associates, Sunderland"},{"key":"4_CR101","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0166-2236(95)80020-3","volume":"18","author":"RL Albin","year":"1995","unstructured":"Albin RL, Young AB, Penney JB (1995) The functional anatomy of disorders of the basal ganglia. Trends Neurosci 18:63\u201364","journal-title":"Trends Neurosci"},{"key":"4_CR102","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/ana.410410514","volume":"41","author":"SE Browne","year":"1997","unstructured":"Browne SE, Bowling AC, MacGarvey U, Baik MJ, Berger SC, Muqit MM, Bird ED, Beal MF (1997) Oxidative damage and metabolic dysfunction in Huntington\u2019s disease: selective vulnerability of the basal ganglia. Ann Neurol 41:646\u2013653","journal-title":"Ann Neurol"},{"key":"4_CR103","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1750-3639.1999.tb00216.x","volume":"9","author":"SE Browne","year":"1999","unstructured":"Browne SE, Ferrante RJ, Beal MF (1999) Oxidative stress in Huntington\u2019s disease. Brain Pathology (Zurich, Switzerland) 9:147\u2013163","journal-title":"Brain Pathology (Zurich, Switzerland)"},{"key":"4_CR104","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1007\/s00415-007-0611-y","volume":"254","author":"N Klepac","year":"2007","unstructured":"Klepac N, Relja M, Klepac R, Hecimovic S, Babic T, Trkulja V (2007) Oxidative stress parameters in plasma of Huntington\u2019s disease patients, asymptomatic Huntington\u2019s disease gene carriers and healthy subjects: a cross-sectional study. J Neurol 254:1676\u20131683","journal-title":"J Neurol"},{"key":"4_CR105","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1046\/j.1471-4159.2001.00689.x","volume":"79","author":"MB Bogdanov","year":"2001","unstructured":"Bogdanov MB, Andreassen OA, Dedeoglu A, Ferrante RJ, Beal MF (2001) Increased oxidative damage to DNA in a transgenic mouse model of Huntington\u2019s disease. J Neurochem 79:1246\u20131249","journal-title":"J Neurochem"},{"key":"4_CR106","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0006-8993(00)02082-5","volume":"862","author":"F P\u00e9rez-Severiano","year":"2000","unstructured":"P\u00e9rez-Severiano F, R\u0131\u0301os C, Segovia J (2000) Striatal oxidative damage parallels the expression of a neurological phenotype in mice transgenic for the mutation of Huntington\u2019s disease. Brain Res 862:234\u2013237","journal-title":"Brain Res"},{"key":"4_CR107","doi-asserted-by":"crossref","unstructured":"Wright, D.J., Renoir, T., Smith, Z.M., Frazier, A.E., Francis, P.S., Thorburn, D.R., McGee, S.L., Hannan, A.J., Gray, L.J., 2015. N-Acetylcysteine improves mitochondrial function and ameliorates behavioral deficits in the R6\/1 mouse model of Huntington\u2019s disease. Transl Psychiatry 5, e492.","DOI":"10.1038\/tp.2014.131"},{"key":"4_CR108","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2990.1995.tb01022.x","volume":"21","author":"AH Schapira","year":"1995","unstructured":"Schapira AH (1995) Oxidative stress in Parkinson\u2019s disease. Neuropathol Appl Neurobiol 21:3\u20139","journal-title":"Neuropathol Appl Neurobiol"},{"key":"4_CR109","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1023\/B:NERE.0000014824.04728.dd","volume":"29","author":"SE Browne","year":"2004","unstructured":"Browne SE, Beal MF (2004) The energetics of Huntington\u2019s disease. Neurochem Res 29:531\u2013546","journal-title":"Neurochem Res"},{"key":"4_CR110","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.brainresbull.2009.07.010","volume":"80","author":"RA Quintanilla","year":"2009","unstructured":"Quintanilla RA, Johnson GVW (2009) Role of mitochondrial dysfunction in the pathogenesis of Huntington\u2019s disease. Brain Res Bull 80:242\u2013247","journal-title":"Brain Res Bull"},{"key":"4_CR111","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/ana.410390317","volume":"39","author":"M Gu","year":"1996","unstructured":"Gu M, Gash MT, Mann VM, Javoy-Agid F, Cooper JM, Schapira AHV (1996) Mitochondrial defect in Huntington\u2019s disease caudate nucleus. Ann Neurol 39:385\u2013389","journal-title":"Ann Neurol"},{"key":"4_CR112","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1212\/WNL.24.9.813","volume":"24","author":"WL Stahl","year":"1974","unstructured":"Stahl WL, Swanson PD (1974) Biochemical abnormalities in Huntington chorea brains. Neurology 24:813\u2013819","journal-title":"Neurology"},{"key":"4_CR113","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/0140-6736(90)92242-A","volume":"336","author":"VM Mann","year":"1990","unstructured":"Mann VM, Cooper JM, Javoy-Agid F, Agid Y, Jenner P, Schapira AHV (1990) Mitochondrial function and parental sex effect in Huntington\u2019s disease. Lancet 336:749","journal-title":"Lancet"},{"key":"4_CR114","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0074-7742(02)53010-5","volume-title":"Mitochondrial function and dysfunction","author":"SE Browne","year":"2002","unstructured":"Browne SE, Beal MF (2002) Toxin-induced mitochondrial dysfunction. In: Mitochondrial function and dysfunction, vol 53, pp 243\u2013279"},{"key":"4_CR115","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1093\/hmg\/ddt242","volume":"22","author":"M Damiano","year":"2013","unstructured":"Damiano M, Diguet E, Malgorn C, D'Aurelio M, Galvan L, Petit F, Benhaim L, Guillermier M, Houitte D, Dufour N, Hantraye P, Canals JM, Alberch J, Delzescaux T, Deglon N, Beal MF, Brouillet E (2013) A role of mitochondrial complex II defects in genetic models of Huntington\u2019s disease expressing N-terminal fragments of mutant huntingtin. Hum Mol Genet 22:3869\u20133882","journal-title":"Hum Mol Genet"},{"key":"4_CR116","doi-asserted-by":"crossref","unstructured":"Aidt FH, Nielsen SMB, Kanters J, Pesta D, Nielsen TT, Norremolle A, Hasholt L, Christiansen M, Hagen CM (2013) Dysfunctional mitochondrial respiration in the striatum of the Huntington\u2019s disease transgenic R6\/2 mouse model. PLoS Curr 5","DOI":"10.1371\/currents.hd.d8917b4862929772c5a2f2a34ef1c201"},{"key":"4_CR117","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0021-9258(18)51740-3","volume":"239","author":"OH Lowry","year":"1964","unstructured":"Lowry OH, Hasselbe FX, Schulz DW, Passonneau JV (1964) Effect of ischemia on known substrates + cofactors of glycolytic pathway in brain. J Biol Chem 239:18\u201330","journal-title":"J Biol Chem"},{"key":"4_CR118","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/j.1471-4159.2007.05182.x","volume":"105","author":"MT Scharf","year":"2008","unstructured":"Scharf MT, Mackiewicz M, Naidoo N, O'Callaghan JP, Pack AI (2008) AMP-activated protein kinase phosphorylation in brain is dependent on method of killing and tissue preparation. J Neurochem 105:833\u2013841","journal-title":"J Neurochem"},{"key":"4_CR119","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1074\/jbc.M111.309849","volume":"287","author":"F Mochel","year":"2012","unstructured":"Mochel F, Durant B, Meng X, O'Callaghan J, Yu H, Brouillet E, Wheeler VC, Humbert S, Schiffmann R, Durr A (2012) Early alterations of brain cellular energy homeostasis in Huntington disease models. J Biol Chem 287:1361\u20131370","journal-title":"J Biol Chem"},{"key":"4_CR120","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ab.2010.04.040","volume":"404","author":"CC Beeson","year":"2010","unstructured":"Beeson CC, Beeson GC, Schnellmann RG (2010) A high-throughput respirometric assay for mitochondrial biogenesis and toxicity. Anal Biochem 404:75\u201381","journal-title":"Anal Biochem"},{"key":"4_CR121","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/j.freeradbiomed.2012.06.008","volume":"53","author":"A Siddiqui","year":"2012","unstructured":"Siddiqui A, Rivera-Sanchez S, Castro MDR, Acevedo-Torres K, Rane A, Torres-Ramos CA, Nicholls DG, Andersen JK, Ayala-Torres S (2012) Mitochondrial DNA damage is associated with reduced mitochondrial bioenergetics in Huntington\u2019s disease. Free Radic Biol Med 53:1478\u20131488","journal-title":"Free Radic Biol Med"},{"key":"4_CR122","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1152\/advan.00052.2006","volume":"30","author":"H Liang","year":"2006","unstructured":"Liang H, Ward WF (2006) PGC-1\u03b1: a key regulator of energy metabolism. Adv Physiol Educ 30:145\u2013151","journal-title":"Adv Physiol Educ"},{"key":"4_CR123","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1210\/er.2002-0012","volume":"24","author":"P Puigserver","year":"2003","unstructured":"Puigserver P, Spiegelman BM (2003) Peroxisome proliferator-activated receptor-\u03b3 coactivator 1\u03b1 (PGC-1\u03b1): transcriptional coactivator and metabolic regulator. Endocr Rev 24:78\u201390","journal-title":"Endocr Rev"},{"key":"4_CR124","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.cmet.2005.05.004","volume":"1","author":"J Lin","year":"2005","unstructured":"Lin J, Handschin C, Spiegelman BM (2005) Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab 1:361\u2013370","journal-title":"Cell Metab"},{"key":"4_CR125","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1101\/gad.1177604","volume":"18","author":"DP Kelly","year":"2004","unstructured":"Kelly DP, Scarpulla RC (2004) Transcriptional regulatory circuits controlling mitochondrial biogenesis and function. Genes Dev 18:357\u2013368","journal-title":"Genes Dev"},{"issue":"4","key":"4_CR126","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.0030101","volume":"3","author":"TC Leone","year":"2005","unstructured":"Leone TC, Lehman JJ, Finck BN, Schaeffer PJ, Wende AR, Boudina S, Courtois M, Wozniak DF, Sambandam N, Bernal-Mizrachi C, Chen Z, Holloszy JO, Medeiros DM, Schmidt RE, Saffitz JE, Abel ED, Semenkovich CF, Kelly DP (2005) PGC-1alpha deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis. PLoS Biol 3(4):e101","journal-title":"PLoS Biol"},{"key":"4_CR127","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.cell.2004.09.013","volume":"119","author":"J Lin","year":"2004","unstructured":"Lin J, Wu PH, Tarr PT, Lindenberg KS, St-Pierre J, Zhang CY, Mootha VK, J\u00e4ger S, Vianna CR, Reznick RM, Cui L, Manieri M, Donovan MX, Wu Z, Cooper MP, Fan MC, Rohas LM, Zavacki AM, Cinti S, Shulman GI, Lowell BB, Krainc D, Spiegelman BM (2004) Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1\u03b1 null mice. Cell 119:121\u2013135","journal-title":"Cell"},{"key":"4_CR128","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cell.2006.09.015","volume":"127","author":"L Cui","year":"2006","unstructured":"Cui L, Jeong H, Borovecki F, Parkhurst CN, Tanese N, Krainc D (2006) Transcriptional repression of PGC-1\u03b1 by mutant Huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 127:59\u201369","journal-title":"Cell"},{"key":"4_CR129","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.cmet.2006.10.004","volume":"4","author":"P Weydt","year":"2006","unstructured":"Weydt P, Pineda VV, Torrence AE, Libby RT, Satterfield TF, Lazarowski E, Gilbert ML, Morton GJ, Bammler TK, Strand AD, Cui L, Beyer RP, Easley CN, Smith AC, Krainc D, Luquet S, Sweet I, Schwartz MW, La Spada AR (2006) Thermoregulatory and metabolic defects in Huntington\u2019s disease transgenic mice implicate PGC-1\u03b1 in Huntington\u2019s disease neurodegeneration. Cell Metab 4:349\u2013362","journal-title":"Cell Metab"},{"key":"4_CR130","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nn.3721","volume":"17","author":"H Yano","year":"2014","unstructured":"Yano H, Baranov SV, Baranova OV, Kim J, Pan Y, Yablonska S, Carlisle DL, Ferrante RJ, Kim AH, Friedlander RM (2014) Inhibition of mitochondrial protein import by mutant huntingtin. Nat Neurosci 17:822\u2013831","journal-title":"Nat Neurosci"},{"key":"4_CR131","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0896-6273(03)00594-4","volume":"40","author":"S Gunawardena","year":"2003","unstructured":"Gunawardena S, Her LS, Brusch RG, Laymon RA, Niesman IR, Gordesky-Gold B, Sintasath L, Bonini NM, Goldstein LSB (2003) Disruption of axonal transport by loss of huntingtin or expression of pathogenic PolyQ proteins in Drosophila. Neuron 40:25\u201340","journal-title":"Neuron"},{"key":"4_CR132","doi-asserted-by":"crossref","unstructured":"Szebenyi G, Morfini GA, Babcock A, Gould M, Selkoe K, Stenoien DL, Young M, Faber PW, MacDonald ME, McPhaul MJ, Brady ST (2003) Neuropathogenic forms of huntingtin and androgen receptor inhibit fast axonal transport. Neuron 40:41\u201352","DOI":"10.1016\/S0896-6273(03)00569-5"},{"key":"4_CR133","doi-asserted-by":"crossref","first-page":"8195","DOI":"10.1128\/MCB.24.18.8195-8209.2004","volume":"24","author":"E Trushina","year":"2004","unstructured":"Trushina E, Dyer RB, Badger JD, Ure D, Eide L, Tran DD, Vrieze BT, Legendre-Guillemin V, McPherson PS, Mandavilli BS, Van Houten B, Zeitlin S, McNiven M, Aebersold R, Hayden M, Parisi JE, Seeberg E, Dragatsis I, Doyle K, Bender A, Chacko C, McMurray CT (2004) Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro. Mol Cell Biol 24:8195\u20138209","journal-title":"Mol Cell Biol"},{"key":"4_CR134","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1093\/hmg\/ddr475","volume":"21","author":"UP Shirendeb","year":"2012","unstructured":"Shirendeb UP, Calkins MJ, Manczak M, Anekonda V, Dufour B, McBride JL, Mao P, Reddy PH (2012) Mutant huntingtin\u2019s interaction with mitochondrial protein Drp1 impairs mitochondrial biogenesis and causes defective axonal transport and synaptic degeneration in Huntington\u2019s disease. Hum Mol Genet 21:406\u2013420","journal-title":"Hum Mol Genet"},{"key":"4_CR135","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.cmet.2011.08.016","volume":"14","author":"M B\u00e9langer","year":"2011","unstructured":"B\u00e9langer M, Allaman I, Magistretti PJ (2011) Brain energy metabolism: focus on astrocyte-neuron metabolic cooperation. Cell Metab 14:724\u2013738","journal-title":"Cell Metab"},{"key":"4_CR136","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1111\/j.1460-9568.2008.06310.x","volume":"27","author":"JM Gil","year":"2008","unstructured":"Gil JM, Rego AC (2008) Mechanisms of neurodegeneration in Huntington\u2019s disease. Eur J Neurosci 27:2803\u20132820","journal-title":"Eur J Neurosci"},{"key":"4_CR137","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1517\/14728220802517901","volume":"8","author":"S Dodd","year":"2008","unstructured":"Dodd S, Dean O, Copolov DL, Malhi GS, Berk M (2008) N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility. Expert Opin Biol Ther 8:1955\u20131962","journal-title":"Expert Opin Biol Ther"},{"key":"4_CR138","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S0306-4522(97)00347-3","volume":"82","author":"ME Rice","year":"1998","unstructured":"Rice ME, Russo-Menna I (1998) Differential compartmentalization of brain ascorbate and glutathione between neurons and glia. Neuroscience 82:1213\u20131223","journal-title":"Neuroscience"},{"key":"4_CR139","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/0306-4522(92)90278-A","volume":"48","author":"S Kato","year":"1992","unstructured":"Kato S, Negishi K, Mawatari K, Kuo CH (1992) A mechanism for glutamate toxicity in the C6 glioma cells involving inhibition of cystine uptake leading to glutathione depletion. Neuroscience 48:903\u2013914","journal-title":"Neuroscience"},{"key":"4_CR140","doi-asserted-by":"crossref","first-page":"L163","DOI":"10.1152\/ajplung.1989.257.4.L163","volume":"257","author":"SM Deneke","year":"1989","unstructured":"Deneke SM, Fanburg BL (1989) Regulation of cellular glutathione. Am J Physiol Lung Cell Mol Physiol 257:L163\u2013L173","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"4_CR141","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1192\/bjp.bp.112.110999","volume":"202","author":"E Papanastasiou","year":"2013","unstructured":"Papanastasiou E, Stone JM, Shergill S (2013) When the drugs don\u2019t work: the potential of glutamatergic antipsychotics in schizophrenia. Br J Psychiatry 202:91\u201393","journal-title":"Br J Psychiatry"},{"key":"4_CR142","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S0140-6736(76)90030-1","volume":"2","author":"E Piperno","year":"1976","unstructured":"Piperno E, Berssenbruegge DA (1976) Reversal of experimental paracetamol toxicosis with N-acetylcysteine. Lancet 2:738\u2013739","journal-title":"Lancet"},{"key":"4_CR143","doi-asserted-by":"crossref","first-page":"628","DOI":"10.4088\/JCP.13m08454","volume":"75","author":"M Berk","year":"2014","unstructured":"Berk M, Dean OM, Cotton SM, Jeavons S, Tanious M, Kohlmann K, Hewitt K, Moss K, Allwang C, Schapkaitz I, Robbins J, Cobb H, Ng F, Dodd S, Bush AI, Malhi GS (2014) The efficacy of adjunctive N-acetylcysteine in major depressive disorder: a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry 75:628\u2013636","journal-title":"J Clin Psychiatry"},{"key":"4_CR144","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/ana.410360305","volume":"36","author":"J Sian","year":"1994","unstructured":"Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, Javoy-Agid F, Jenner P, Marsden CD (1994) Alterations in glutathione levels in Parkinson\u2019s disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 36:348\u2013355","journal-title":"Ann Neurol"},{"key":"4_CR145","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/j.freeradbiomed.2012.09.004","volume":"53","author":"M Ribeiro","year":"2012","unstructured":"Ribeiro M, Rosenstock TR, Cunha-Oliveira T, Ferreira IL, Oliveira CR, Rego AC (2012) Glutathione redox cycle dysregulation in Huntington\u2019s disease knock-in striatal cells. Free Radic Biol Med 53:1857\u20131867","journal-title":"Free Radic Biol Med"},{"key":"4_CR146","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1111\/j.1471-4159.2006.04323.x","volume":"100","author":"I Tkac","year":"2007","unstructured":"Tkac I, Dubinsky JM, Keene CD, Gruetter R, Low WC (2007) Neurochemical changes in Huntington R6\/2 mouse striatum detected by in vivo (1)H NMR spectroscopy. J Neurochem 100:1397\u20131406","journal-title":"J Neurochem"},{"key":"4_CR147","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.neulet.2005.05.065","volume":"386","author":"YS Choo","year":"2005","unstructured":"Choo YS, Mao Z, Johnson GV, Lesort M (2005) Increased glutathione levels in cortical and striatal mitochondria of the R6\/2 Huntington\u2019s disease mouse model. Neurosci Lett 386:63\u201368","journal-title":"Neurosci Lett"},{"key":"4_CR148","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0959-4388(00)00215-4","volume":"11","author":"S Cull-Candy","year":"2001","unstructured":"Cull-Candy S, Brickley S, Farrant M (2001) NMDA receptor subunits: diversity, development and disease. Curr Opin Neurobiol 11:327\u2013335","journal-title":"Curr Opin Neurobiol"},{"key":"4_CR149","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/jnr.1244","volume":"66","author":"C Cepeda","year":"2001","unstructured":"Cepeda C, Ariano MA, Calvert CR, Flores-Hernandez J, Chandler SH, Leavitt BR, Hayden MR, Levine MS (2001) NMDA receptor function in mouse models of Huntington disease. J Neurosci Res 66:525\u2013539","journal-title":"J Neurosci Res"},{"key":"4_CR150","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/jnr.20651","volume":"82","author":"AJ Starling","year":"2005","unstructured":"Starling AJ, Andre WM, Cepeda C, de Lima M, Chandler SH, Levine MS (2005) Alterations in N-methyl-D-aspartate receptor sensitivity and magnesium blockade occur early in development in the R6\/2 mouse model of Huntington\u2019s disease. J Neurosci Res 82:377\u2013386","journal-title":"J Neurosci Res"},{"key":"4_CR151","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1152\/jn.01118.2005","volume":"95","author":"VM Andre","year":"2006","unstructured":"Andre VM, Cepeda C, Venegas A, Gomez Y, Levine MS (2006) Altered cortical glutamate receptor function in the r6\/2 model of Huntington\u2019s disease. J Neurophysiol 95:2108\u20132119","journal-title":"J Neurophysiol"},{"key":"4_CR152","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nrn2911","volume":"11","author":"GE Hardingham","year":"2010","unstructured":"Hardingham GE, Bading H (2010) Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat Rev Neurosci 11:682\u2013696","journal-title":"Nat Rev Neurosci"},{"key":"4_CR153","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00213-012-2754-5","volume":"224","author":"E Venzala","year":"2012","unstructured":"Venzala E, Garcia-Garcia AL, Elizalde N, Delagrange P, Tordera RM (2012) Chronic social defeat stress model: behavioral features, antidepressant action, and interaction with biological risk factors. Psychopharmacology 224:313\u2013325","journal-title":"Psychopharmacology"},{"key":"4_CR154","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.neuron.2007.01.025","volume":"53","author":"SJ Zhang","year":"2007","unstructured":"Zhang SJ, Steijaert MN, Lau D, Schutz G, Delucinge-Vivier C, Descombes P, Bading H (2007) Decoding NMDA receptor signaling: identification of genomic programs specifying neuronal survival and death. Neuron 53:549\u2013562","journal-title":"Neuron"},{"key":"4_CR155","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/nn2071","volume":"11","author":"S Papadia","year":"2008","unstructured":"Papadia S, Soriano FX, Leveille F, Martel M-A, Dakin KA, Hansen HH, Kaindl A, Sifringer M, Fowler J, Stefovska V, McKenzie G, Craigon M, Corriveau R, Ghazal P, Horsburgh K, Yankner BA, Wyllie DJA, Ikonomidou C, Hardingham GE (2008) Synaptic NMDA receptor activity boosts intrinsic antioxidant defenses. Nat Neurosci 11:476\u2013487","journal-title":"Nat Neurosci"},{"key":"4_CR156","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1523\/JNEUROSCI.0802-09.2009","volume":"29","author":"D Lau","year":"2009","unstructured":"Lau D, Bading H (2009) Synaptic activity-mediated suppression of p53 and induction of nuclear calcium-regulated neuroprotective genes promote survival through inhibition of mitochondrial permeability transition. J Neurosci 29:4420\u20134429","journal-title":"J Neurosci"},{"key":"4_CR157","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1212\/WNL.0b013e3182697986","volume":"79","author":"NA Aziz","year":"2012","unstructured":"Aziz NA, Roos RAC, Gusella JF, Lee J-M, Macdonald ME (2012) CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. Neurology 79:952; author reply 952\u2013953","journal-title":"Neurology"},{"key":"4_CR158","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1189\/jlb.0212100","volume":"92","author":"W Beumer","year":"2012","unstructured":"Beumer W, Gibney SM, Drexhage RC, Pont-Lezica L, Doorduin J, Klein HC, Steiner J, Connor TJ, Harkin A, Versnel MA, Drexhage HA (2012) The immune theory of psychiatric diseases: a key role for activated microglia and circulating monocytes. J Leukoc Biol 92:959\u2013975","journal-title":"J Leukoc Biol"},{"key":"4_CR159","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jns.2012.08.034","volume":"323","author":"C Sidiropoulos","year":"2012","unstructured":"Sidiropoulos C, Lewitt P, Hashimoto K (2012) Abnormal apocrine secretory cell mitochondria in a Huntington disease patient. J Neurol Sci 323:261\u2013263","journal-title":"J Neurol Sci"},{"key":"4_CR160","doi-asserted-by":"crossref","unstructured":"Tansey, K.E., Guipponi, M., Perroud, N., Bondolfi, G., Domenici, E., Evans, D., Hall, S.K., Hauser, J., Henigsberg, N., Hu, X., Jerman, B., Maier, W., Mors, O., O'Donovan, M., Peters, T.J., Placentino, A., Rietschel, M., Souery, D., Aitchison, K.J., Craig, I., Farmer, A., Wendland, J.R., Malafosse, A., Holmans, P., Lewis, G., Lewis, C.M., Stensbol, T.B., Kapur, S., McGuffin, P., Uher, R., 2012. Genetic predictors of response to serotonergic and noradrenergic antidepressants in major depressive disorder: a genome-wide analysis of individual-level data and a meta-analysis. PLoS Med 9, e1001326.","DOI":"10.1371\/journal.pmed.1001326"},{"key":"4_CR161","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.neuron.2010.01.008","volume":"65","author":"AJ Milnerwood","year":"2010","unstructured":"Milnerwood AJ, Gladding CM, Pouladi MA, Kaufman AM, Hines RM, Boyd JD, Ko RWY, Vasuta OC, Graham RK, Hayden MR, Murphy TH, Raymond LA (2010) Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington\u2019s disease mice. Neuron 65:178\u2013190","journal-title":"Neuron"},{"key":"4_CR162","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/0891988712455236","volume":"25","author":"LB Zahodne","year":"2012","unstructured":"Zahodne LB, Marsiske M, Okun MS, Bowers D (2012) Components of depression in Parkinson disease. J Geriatr Psychiatry Neurol 25:131\u2013137","journal-title":"J Geriatr Psychiatry Neurol"},{"issue":"Suppl 3","key":"4_CR163","doi-asserted-by":"crossref","first-page":"S487","DOI":"10.1016\/j.euroneuro.2012.07.008","volume":"22","author":"P Fossati","year":"2012","unstructured":"Fossati P (2012) Neural correlates of emotion processing: from emotional to social brain. Eur Neuropsychopharmacol 22(Suppl 3):S487\u2013S491","journal-title":"Eur Neuropsychopharmacol"},{"key":"4_CR164","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1242\/dmm.010124","volume":"5","author":"JE Vance","year":"2012","unstructured":"Vance JE (2012) Dysregulation of cholesterol balance in the brain: contribution to neurodegenerative diseases. Dis Model Mech 5:746\u2013755","journal-title":"Dis Model Mech"},{"key":"4_CR165","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1046\/j.1471-4159.1999.0721890.x","volume":"72","author":"NS Chen","year":"1999","unstructured":"Chen NS, Luo T, Wellington C, Metzler M, McCutcheon K, Hayden MR, Raymond LA (1999) Subtype-specific enhancement of NMDA receptor currents by mutant Huntingtin. J Neurochem 72:1890\u20131898","journal-title":"J Neurochem"},{"key":"4_CR166","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1152\/physrev.00007.2013","volume":"93","author":"RJ Vandenberg","year":"2013","unstructured":"Vandenberg RJ, Ryan RM (2013) Mechanisms of glutamate transport. Physiol Rev 93:1621\u20131657","journal-title":"Physiol Rev"},{"key":"4_CR167","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1042\/bst0290717","volume":"29","author":"GJ McBean","year":"2001","unstructured":"McBean GJ, Flynn J (2001) Molecular mechanisms of cystine transport. Biochem Soc Trans 29:717\u2013722","journal-title":"Biochem Soc Trans"},{"key":"4_CR168","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1006\/nbdi.2001.0430","volume":"8","author":"JC Lievens","year":"2001","unstructured":"Lievens JC, Woodman B, Mahal A, Spasic-Boscovic O, Samuel D, Kerkerian-Le Goff L, Bates GP (2001) Impaired glutamate uptake in the R6 Huntington\u2019s disease transgenic mice. Neurobiol Dis 8:807\u2013821","journal-title":"Neurobiol Dis"},{"key":"4_CR169","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1093\/brain\/awf180","volume":"125","author":"PF Behrens","year":"2002","unstructured":"Behrens PF, Franz P, Woodman B, Lindenberg KS, Landwehrmeyer GB (2002) Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation. Brain 125:1908\u20131922","journal-title":"Brain"},{"key":"4_CR170","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nature03180","volume":"433","author":"JD Rothstein","year":"2005","unstructured":"Rothstein JD, Patel S, Regan MR, Haenggeli C, Huang YH, Bergles DE, Jin L, Hoberg MD, Vidensky S, Chung DS, Toan SV, Bruijn LI, Su ZZ, Gupta P, Fisher PB (2005) Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 433:73\u201377","journal-title":"Nature"},{"key":"4_CR171","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/j.1471-4159.2012.07691.x","volume":"121","author":"BR Miller","year":"2012","unstructured":"Miller BR, Dorner JL, Bunner KD, Gaither TW, Klein EL, Barton SJ, Rebec GV (2012) Up-regulation of GLT1 reverses the deficit in cortically evoked striatal ascorbate efflux in the R6\/2 mouse model of Huntington\u2019s disease. J Neurochem 121:629\u2013638","journal-title":"J Neurochem"},{"key":"4_CR172","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.neuroscience.2008.02.004","volume":"153","author":"BR Miller","year":"2008","unstructured":"Miller BR, Dorner JL, Shou M, Sari Y, Barton SJ, Sengelaub DR, Kennedy RT, Rebec GV (2008) Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington\u2019s disease phenotype in the R6\/2 mouse. Neuroscience 153:329\u2013337","journal-title":"Neuroscience"},{"key":"4_CR173","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1089\/ars.2013.5387","volume":"19","author":"GV Rebec","year":"2013","unstructured":"Rebec GV (2013) Dysregulation of corticostriatal ascorbate release and glutamate uptake in transgenic models of Huntington\u2019s disease. Antioxid Redox Signal 19:2115\u20132128","journal-title":"Antioxid Redox Signal"},{"key":"4_CR174","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1423-0127-17-62","volume":"17","author":"Y Sari","year":"2010","unstructured":"Sari Y, Prieto AL, Barton SJ, Miller BR, Rebec GV (2010) Ceftriaxone-induced up-regulation of cortical and striatal GLT1 in the R6\/2 model of Huntington\u2019s disease. J Biomed Sci 17:62","journal-title":"J Biomed Sci"},{"key":"4_CR175","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.nbd.2010.05.027","volume":"40","author":"K Huang","year":"2010","unstructured":"Huang K, Kang MH, Askew C, Kang R, Sanders SS, Wan J, Davis NG, Hayden MR (2010) Palmitoylation and function of glial glutamate transporter-1 is reduced in the YAC128 mouse model of Huntington disease. Neurobiol Dis 40:207\u2013215","journal-title":"Neurobiol Dis"},{"key":"4_CR176","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1111\/ejn.12202","volume":"38","author":"GT Petr","year":"2013","unstructured":"Petr GT, Schultheis LA, Hussey KC, Sun Y, Dubinsky JM, Aoki C, Rosenberg PA (2013) Decreased expression of GLT-1 in the R6\/2 model of Huntington\u2019s disease does not worsen disease progression. Eur J Neurosci 38:2477\u20132490","journal-title":"Eur J Neurosci"},{"key":"4_CR177","first-page":"308","volume":"311","author":"S Bannai","year":"1984","unstructured":"Bannai S, Christensen HN, Vadgama JV, Ellory JC, Englesberg E, Guidotti GG, Gazzola GC, Kilberg MS, Lajtha A, Sacktor B (1984) Amino acid transport systems. Nature 311:308","journal-title":"Nature"},{"key":"4_CR178","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1089\/ars.2011.4391","volume":"18","author":"J Lewerenz","year":"2013","unstructured":"Lewerenz J, Hewett SJ, Huang Y, Lambros M, Gout PW, Kalivas PW, Massie A, Smolders I, Methner A, Pergande M, Smith SB, Ganapathy V, Maher P (2013) The cystine\/glutamate antiporter system x(c)(\u2212) in health and disease: from molecular mechanisms to novel therapeutic opportunities. Antioxid Redox Signal 18:522\u2013555","journal-title":"Antioxid Redox Signal"},{"key":"4_CR179","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nrm3391","volume":"13","author":"BD Paul","year":"2012","unstructured":"Paul BD, Snyder SH (2012) H2S signalling through protein sulfhydration and beyond. Nat Rev Mol Cell Biol 13:499\u2013507","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"7498","key":"4_CR180","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature13136","volume":"509","author":"BD Paul","year":"2014","unstructured":"Paul BD, Sbodio JI, Xu R, Vandiver MS, Cha JY, Snowman AM, Snyder SH (2014) Cystathionine [ggr]-lyase deficiency mediates neurodegeneration in Huntington\u2019s disease. Nature 509(7498):96\u2013100","journal-title":"Nature"},{"key":"4_CR181","doi-asserted-by":"crossref","unstructured":"Wright DW, Gray LJ, Li SS, Crouch PJ, Finkelstein D, Roberts B, Smith ZM, Francis PS, McGee SL, Renoir T, Hannan AJ (2016) Cystine-mediated therapeutic modulation of glutamatergic dysfunction and depressive behaviour in Huntington\u2019s disease. Human Mol Genet (in press)","DOI":"10.1093\/hmg\/ddw144"},{"key":"4_CR182","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/j.1471-4159.2006.03921.x","volume":"98","author":"J Lewerenz","year":"2006","unstructured":"Lewerenz J, Klein M, Methner A (2006) Cooperative action of glutamate transporters and cystine\/glutamate antiporter system X-c(\u2212) protects from oxidative glutamate toxicity. J Neurochem 98:916\u2013925","journal-title":"J Neurochem"},{"key":"4_CR183","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jneuroim.2006.11.013","volume":"184","author":"MM Esiri","year":"2007","unstructured":"Esiri MM (2007) The interplay between inflammation and neurodegeneration in CNS disease. J Neuroimmunol 184:4\u201316","journal-title":"J Neuroimmunol"},{"key":"4_CR184","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/nrn752","volume":"3","author":"MD Nguyen","year":"2002","unstructured":"Nguyen MD, Julien J-P, Rivest S (2002) Innate immunity: the missing link in neuroprotection and neurodegeneration? Nat Rev Neurosci 3:216\u2013227","journal-title":"Nat Rev Neurosci"},{"key":"4_CR185","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.pneurobio.2005.06.004","volume":"76","author":"ML Block","year":"2005","unstructured":"Block ML, Hong J-S (2005) Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog Neurobiol 76:77\u201398","journal-title":"Prog Neurobiol"},{"key":"4_CR186","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1471-4159.2005.03622.x","volume":"96","author":"J Falsig","year":"2006","unstructured":"Falsig J, P\u00f6rzgen P, Lund S, Schrattenholz A, Leist M (2006) The inflammatory transcriptome of reactive murine astrocytes and implications for their innate immune function. J Neurochem 96:893\u2013907","journal-title":"J Neurochem"},{"key":"4_CR187","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nrn2038","volume":"8","author":"ML Block","year":"2007","unstructured":"Block ML, Zecca L, Hong J-S (2007) Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 8:57\u201369","journal-title":"Nat Rev Neurosci"},{"key":"4_CR188","doi-asserted-by":"crossref","unstructured":"Ellrichmann G, Reick C, Saft C, Linker RA (2013) The role of the immune system in Huntington\u2019s disease. Clin Dev Immunol 2013:541259","DOI":"10.1155\/2013\/541259"},{"key":"4_CR189","doi-asserted-by":"crossref","unstructured":"Labadorf, A., Hoss, A.G., Lagomarsino, V., Latourelle, J.C., Hadzi, T.C., Bregu, J., MacDonald, M.E., Gusella, J.F., Chen, J.F., Akbarian, S., Weng, Z., Myers, R.H., 2015. RNA sequence analysis of human Huntington disease brain reveals an extensive increase in inflammatory and developmental gene expression. PLoS One 10, e0143563.","DOI":"10.1371\/journal.pone.0143563"},{"key":"4_CR190","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/jnen\/60.2.161","volume":"60","author":"E Sapp","year":"2001","unstructured":"Sapp E, Kegel KB, Aronin N, Hashikawa T, Uchiyama Y, Tohyama K, Bhide PG, Vonsattel JP, DiFiglia M (2001) Early and progressive accumulation of reactive microglia in the Huntington disease brain. J Neuropathol Exp Neurol 60:161\u2013172","journal-title":"J Neuropathol Exp Neurol"},{"issue":"621","key":"4_CR191","first-page":"e617","volume":"33","author":"AD Kraft","year":"2012","unstructured":"Kraft AD, Kaltenbach LS, Lo DC, Harry GJ (2012) Activated microglia proliferate at neurites of mutant huntingtin-expressing neurons. Neurobiol Aging 33(621):e617\u2013e633","journal-title":"Neurobiol Aging"},{"key":"4_CR192","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1212\/01.wnl.0000222734.56412.17","volume":"66","author":"N Pavese","year":"2006","unstructured":"Pavese N, Gerhard A, Tai Y, Ho AK, Turkheimer F, Barker RA, Brooks DJ, Piccini P (2006) Microglial activation correlates with severity in Huntington disease\u00a0\u2013 a clinical and PET study. Neurology 66:1638\u20131643","journal-title":"Neurology"},{"key":"4_CR193","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.brainresbull.2006.10.029","volume":"72","author":"YF Tai","year":"2007","unstructured":"Tai YF, Pavese N, Gerhard A, Tabrizi SJ, Barker RA, Brooks DJ, Piccini P (2007) Imaging microglial activation in Huntington\u2019s disease. Brain Res Bull 72:148\u2013151","journal-title":"Brain Res Bull"},{"key":"4_CR194","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1093\/brain\/awm044","volume":"130","author":"YF Tai","year":"2007","unstructured":"Tai YF, Pavese N, Gerhard A, Tabrizi SJ, Barker RA, Brooks DJ, Piccini P (2007) Microglial activation in presymptomatic Huntington\u2019s disease gene carriers. Brain 130:1759\u20131766","journal-title":"Brain"},{"key":"4_CR195","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.nbd.2015.08.011","volume":"83","author":"M Politis","year":"2015","unstructured":"Politis M, Lahiri N, Niccolini F, Su P, Wu K, Giannetti P, Scahill RI, Turkheimer FE, Tabrizi SJ, Piccini P (2015) Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington\u2019s disease gene carriers. Neurobiol Dis 83:115\u2013121","journal-title":"Neurobiol Dis"},{"key":"4_CR196","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1084\/jem.20080178","volume":"205","author":"M Bjorkqvist","year":"2008","unstructured":"Bjorkqvist M, Wild EJ, Thiele J, Silvestroni A, Andre R, Lahiri N, Raibon E, Lee RV, Benn CL, Soulet D, Magnusson A, Woodman B, Landles C, Pouladi MA, Hayden MR, Khalili-Shirazi A, Lowdell MW, Brundin P, Bates GP, Leavitt BR, M\u00f6ller T, Tabrizi SJ (2008) A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington\u2019s disease. J Exp Med 205:1869\u20131877","journal-title":"J Exp Med"},{"key":"4_CR197","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1097\/WNR.1090b1013e32832e32834ee","volume":"20","author":"A Silvestroni","year":"2009","unstructured":"Silvestroni A, Faull RLM, Strand AD, Moller T (2009) Distinct neuroinflammatory profile in post-mortem human Huntington\u2019s disease. Neuroreport 20:1098\u20131103. doi: 10.1097\/WNR.1090b1013e32832e32834ee","journal-title":"Neuroreport"},{"key":"4_CR198","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.nbd.2014.10.012","volume":"73","author":"U Trager","year":"2015","unstructured":"Trager U, Andre R, Magnusson-Lind A, Miller JR, Connolly C, Weiss A, Grueninger S, Silajdzic E, Smith DL, Leavitt BR, Bates GP, Bjorkqvist M, Tabrizi SJ (2015) Characterisation of immune cell function in fragment and full-length Huntington\u2019s disease mouse models. Neurobiol Dis 73:388\u2013398","journal-title":"Neurobiol Dis"},{"key":"4_CR199","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3233\/JHD-150153","volume":"4","author":"T Renoir","year":"2015","unstructured":"Renoir T, Pang TY, Shikano Y, Li S, Hannan AJ (2015) Loss of the sexually dimorphic neuro-inflammatory response in a transgenic mouse model of Huntington\u2019s disease. J Huntingtons Dis 4:297\u2013303","journal-title":"J Huntingtons Dis"},{"key":"4_CR200","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1471-4159.2009.06442.x","volume":"112","author":"CM Forrest","year":"2010","unstructured":"Forrest CM, Mackay GM, Stoy N, Spiden SL, Taylor R, Stone TW, Darlington LG (2010) Blood levels of kynurenines, interleukin-23 and soluble human leucocyte antigen-G at different stages of Huntington\u2019s disease. J Neurochem 112:112\u2013122","journal-title":"J Neurochem"},{"key":"4_CR201","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.neuroscience.2016.03.031","volume":"325","author":"C Connolly","year":"2016","unstructured":"Connolly C, Magnusson-Lind A, Lu G, Wagner PK, Southwell AL, Hayden MR, Bjorkqvist M, Leavitt BR (2016) Enhanced immune response to MMP3 stimulation in microglia expressing mutant huntingtin. Neuroscience 325:74\u201388","journal-title":"Neuroscience"},{"key":"4_CR202","doi-asserted-by":"crossref","first-page":"454","DOI":"10.2174\/1389450115666140115113734","volume":"15","author":"J Gil-Mohapel","year":"2014","unstructured":"Gil-Mohapel J, Brocardo PS, Christie BR (2014) The role of oxidative stress in Huntington\u2019s disease: are antioxidants good therapeutic candidates? Curr Drug Targets 15:454\u2013468","journal-title":"Curr Drug Targets"},{"key":"4_CR203","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.nbd.2014.06.022","volume":"71","author":"Z Lu","year":"2014","unstructured":"Lu Z, Marks E, Chen J, Moline J, Barrows L, Raisbeck M, Volitakis I, Cherny RA, Chopra V, Bush AI, Hersch S, Fox JH (2014) Altered selenium status in Huntington\u2019s disease: neuroprotection by selenite in the N171-82Q mouse model. Neurobiol Dis 71:34\u201342","journal-title":"Neurobiol Dis"},{"key":"4_CR204","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/jnc.12190","volume":"125","author":"J Jin","year":"2013","unstructured":"Jin J, Albertz J, Guo Z, Peng Q, Rudow G, Troncoso JC, Ross CA, Duan W (2013) Neuroprotective effects of PPAR-gamma agonist rosiglitazone in N171-82Q mouse model of Huntington\u2019s disease. J Neurochem 125:410\u2013419","journal-title":"J Neurochem"},{"key":"4_CR205","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/hmg\/ddq322","volume":"19","author":"MC Chiang","year":"2010","unstructured":"Chiang MC, Chen CM, Lee MR, Chen HW, Chen HM, Wu YS, Hung CH, Kang JJ, Chang CP, Chang C, Wu YR, Tsai YS, Chern Y (2010) Modulation of energy deficiency in Huntington\u2019s disease via activation of the peroxisome proliferator-activated receptor gamma. Hum Mol Genet 19:4043\u20134058","journal-title":"Hum Mol Genet"},{"key":"4_CR206","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00401-010-0788-5","volume":"121","author":"J Lee","year":"2011","unstructured":"Lee J, Kosaras B, Del Signore SJ, Cormier K, McKee A, Ratan RR, Kowall NW, Ryu H (2011) Modulation of lipid peroxidation and mitochondrial function improves neuropathology in Huntington\u2019s disease mice. Acta Neuropathol 121:487\u2013498","journal-title":"Acta Neuropathol"},{"key":"4_CR207","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.celrep.2012.10.001","volume":"2","author":"Z Xun","year":"2012","unstructured":"Xun Z, Rivera-Sanchez S, Ayala-Pena S, Lim J, Budworth H, Skoda EM, Robbins PD, Niedernhofer LJ, Wipf P, McMurray CT (2012) Targeting of XJB-5-131 to mitochondria suppresses oxidative DNA damage and motor decline in a mouse model of Huntington\u2019s disease. Cell Rep 2:1137\u20131142","journal-title":"Cell Rep"},{"key":"4_CR208","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1750-1326-7-12","volume":"7","author":"MA Hickey","year":"2012","unstructured":"Hickey MA, Zhu C, Medvedeva V, Lerner RP, Patassini S, Franich NR, Maiti P, Frautschy SA, Zeitlin S, Levine MS, Chesselet MF (2012) Improvement of neuropathology and transcriptional deficits in CAG 140 knock-in mice supports a beneficial effect of dietary curcumin in Huntington\u2019s disease. Mol Neurodegener 7:12","journal-title":"Mol Neurodegener"},{"key":"4_CR209","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.expneurol.2010.05.006","volume":"225","author":"DJ Ho","year":"2010","unstructured":"Ho DJ, Calingasan NY, Wille E, Dumont M, Beal MF (2010) Resveratrol protects against peripheral deficits in a mouse model of Huntington\u2019s disease. Exp Neurol 225:74\u201384","journal-title":"Exp Neurol"},{"key":"4_CR210","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.nbd.2012.03.025","volume":"47","author":"A Reiner","year":"2012","unstructured":"Reiner A, Lafferty DC, Wang HB, Del Mar N, Deng YP (2012) The group 2 metabotropic glutamate receptor agonist LY379268 rescues neuronal, neurochemical and motor abnormalities in R6\/2 Huntington\u2019s disease mice. Neurobiol Dis 47:75\u201391","journal-title":"Neurobiol Dis"},{"key":"4_CR211","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.nbd.2014.08.021","volume":"73","author":"JG Doria","year":"2015","unstructured":"Doria JG, de Souza JM, Andrade JN, Rodrigues HA, Guimaraes IM, Carvalho TG, Guatimosim C, Dobransky T, Ribeiro FM (2015) The mGluR5 positive allosteric modulator, CDPPB, ameliorates pathology and phenotypic signs of a mouse model of Huntington\u2019s disease. Neurobiol Dis 73:163\u2013173","journal-title":"Neurobiol Dis"},{"key":"4_CR212","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/bph.12164","volume":"169","author":"JG Doria","year":"2013","unstructured":"Doria JG, Silva FR, de Souza JM, Vieira LB, Carvalho TG, Reis HJ, Pereira GS, Dobransky T, Ribeiro FM (2013) Metabotropic glutamate receptor 5 positive allosteric modulators are neuroprotective in a mouse model of Huntington\u2019s disease. Br J Pharmacol 169:909\u2013921","journal-title":"Br J Pharmacol"},{"key":"4_CR213","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.brainres.2004.06.005","volume":"1019","author":"J Schiefer","year":"2004","unstructured":"Schiefer J, Sprunken A, Puls C, Luesse HG, Milkereit A, Milkereit E, Johann V, Kosinski CM (2004) The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington\u2019s disease. Brain Res 1019:246\u2013254","journal-title":"Brain Res"},{"key":"4_CR214","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1093\/hmg\/ddt598","volume":"23","author":"FM Ribeiro","year":"2014","unstructured":"Ribeiro FM, Devries RA, Hamilton A, Guimaraes IM, Cregan SP, Pires RG, Ferguson SS (2014) Metabotropic glutamate receptor 5 knockout promotes motor and biochemical alterations in a mouse model of Huntington\u2019s disease. Hum Mol Genet 23:2030\u20132042","journal-title":"Hum Mol Genet"},{"key":"4_CR215","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/mds.10229","volume":"17","author":"J Schiefer","year":"2002","unstructured":"Schiefer J, Landwehrmeyer GB, L\u00fcesse HG, Spr\u00fcnken A, Puls C, Milkereit A, Milkereit E, Kosinski CM (2002) Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington\u2019s disease. Mov Disord 17:748\u2013757","journal-title":"Mov Disord"},{"key":"4_CR216","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1038\/nm.3246","volume":"19","author":"S Marco","year":"2013","unstructured":"Marco S, Giralt A, Petrovic MM, Pouladi MA, Martinez-Turrillas R, Martinez-Hernandez J, Kaltenbach LS, Torres-Peraza J, Graham RK, Watanabe M, Lujan R, Nakanishi N, Lipton SA, Lo DC, Hayden MR, Alberch J, Wesseling JF, Perez-Otano I (2013) Suppressing aberrant GluN3A expression rescues synaptic and behavioral impairments in Huntington\u2019s disease models. Nat Med 19:1030\u20131038","journal-title":"Nat Med"},{"key":"4_CR217","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.brainres.2012.07.026","volume":"1473","author":"A Reiner","year":"2012","unstructured":"Reiner A, Wang HB, Del Mar N, Sakata K, Yoo W, Deng YP (2012) BDNF may play a differential role in the protective effect of the mGluR2\/3 agonist LY379268 on striatal projection neurons in R6\/2 Huntington\u2019s disease mice. Brain Res 1473:161\u2013172","journal-title":"Brain Res"},{"key":"4_CR218","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/mds.26174","volume":"30","author":"R Reilmann","year":"2015","unstructured":"Reilmann R, Rouzade-Dominguez ML, Saft C, Sussmuth SD, Priller J, Rosser A, Rickards H, Schols L, Pezous N, Gasparini F, Johns D, Landwehrmeyer GB, Gomez-Mancilla B (2015) A randomized, placebo-controlled trial of AFQ056 for the treatment of chorea in Huntington\u2019s disease. Mov Disord 30:427\u2013431","journal-title":"Mov Disord"},{"key":"4_CR219","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00011-011-0323-8","volume":"60","author":"JR Palacio","year":"2011","unstructured":"Palacio JR, Markert UR, Martinez P (2011) Anti-inflammatory properties of N-acetylcysteine on lipopolysaccharide-activated macrophages. Inflamm Res 60:695\u2013704","journal-title":"Inflamm Res"},{"key":"4_CR220","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.archoralbio.2016.03.017","volume":"68","author":"S Pinar Karapinar","year":"2016","unstructured":"Pinar Karapinar S, Ulum YZ, Ozcelik B, Dogan Buzoglu H, Ceyhan D, Balci Peynircioglu B, Aksoy Y (2016) The effect of N-acetylcysteine and calcium hydroxide on TNF-alpha and TGF-beta1 in lipopolysaccharide-activated macrophages. Arch Oral Biol 68:48\u201354","journal-title":"Arch Oral Biol"},{"key":"4_CR221","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1016\/j.bbagen.2013.04.016","volume":"1830","author":"Y Samuni","year":"2013","unstructured":"Samuni Y, Goldstein S, Dean OM, Berk M (2013) The chemistry and biological activities of N-acetylcysteine. Biochim Biophys Acta 1830:4117\u20134129","journal-title":"Biochim Biophys Acta"},{"key":"4_CR222","doi-asserted-by":"crossref","first-page":"10514","DOI":"10.1523\/JNEUROSCI.3178-06.2006","volume":"26","author":"AY Shih","year":"2006","unstructured":"Shih AY, Erb H, Sun X, Toda S, Kalivas PW, Murphy TH (2006) Cystine\/glutamate exchange modulates glutathione supply for neuroprotection from oxidative stress and cell proliferation. J Neurosci 26:10514\u201310523","journal-title":"J Neurosci"},{"key":"4_CR223","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.tips.2013.01.001","volume":"34","author":"M Berk","year":"2013","unstructured":"Berk M, Malhi GS, Gray LJ, Dean OM (2013) The promise of N-acetylcysteine in neuropsychiatry. Trends Pharmacol Sci 34:167\u2013177","journal-title":"Trends Pharmacol Sci"},{"key":"4_CR224","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.nbd.2011.03.017","volume":"43","author":"PH Reinhart","year":"2011","unstructured":"Reinhart PH, Kaltenbach LS, Essrich C, Dunn DE, Eudailey JA, DeMarco CT, Turmel GJ, Whaley JC, Wood A, Cho S, Lo DC (2011) Identification of anti-inflammatory targets for Huntington\u2019s disease using a brain slice-based screening assay. Neurobiol Dis 43:248\u2013256","journal-title":"Neurobiol Dis"},{"key":"4_CR225","doi-asserted-by":"crossref","first-page":"4328","DOI":"10.1093\/hmg\/ddu151","volume":"23","author":"HY Hsiao","year":"2014","unstructured":"Hsiao HY, Chiu FL, Chen CM, Wu YR, Chen HM, Chen YC, Kuo HC, Chern Y (2014) Inhibition of soluble tumor necrosis factor is therapeutic in Huntington\u2019s disease. Hum Mol Genet 23:4328\u20134344","journal-title":"Hum Mol Genet"},{"key":"4_CR226","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1093\/hmg\/ddt667","volume":"23","author":"M Maheshwari","year":"2014","unstructured":"Maheshwari M, Bhutani S, Das A, Mukherjee R, Sharma A, Kino Y, Nukina N, Jana NR (2014) Dexamethasone induces heat shock response and slows down disease progression in mouse and fly models of Huntington\u2019s disease. Hum Mol Genet 23:2737\u20132751","journal-title":"Hum Mol Genet"},{"key":"4_CR227","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.nbd.2004.07.011","volume":"17","author":"F Norflus","year":"2004","unstructured":"Norflus F, Nanje A, Gutekunst CA, Shi G, Cohen J, Bejarano M, Fox J, Ferrante RJ, Hersch SM (2004) Anti-inflammatory treatment with acetylsalicylate or rofecoxib is not neuroprotective in Huntington\u2019s disease transgenic mice. Neurobiol Dis 17:319\u2013325","journal-title":"Neurobiol Dis"}],"container-title":["Advances in Neurobiology","Neurodegenerative Diseases"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-319-57193-5_4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T09:59:43Z","timestamp":1659175183000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-319-57193-5_4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"ISBN":["9783319571911","9783319571935"],"references-count":227,"URL":"https:\/\/doi.org\/10.1007\/978-3-319-57193-5_4","relation":{},"ISSN":["2190-5215","2190-5223"],"issn-type":[{"value":"2190-5215","type":"print"},{"value":"2190-5223","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}